Sanara MedTech (NASDAQ:SMTI - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect Sanara MedTech to post earnings of ($0.31) per share and revenue of $23.48 million for the quarter.
Sanara MedTech (NASDAQ:SMTI - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. The company had revenue of $26.31 million for the quarter, compared to analysts' expectations of $22.75 million. On average, analysts expect Sanara MedTech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Sanara MedTech Stock Performance
Shares of Sanara MedTech stock opened at $31.85 on Wednesday. The business has a 50-day simple moving average of $31.08 and a 200 day simple moving average of $33.46. Sanara MedTech has a one year low of $25.86 and a one year high of $39.08. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02. The firm has a market capitalization of $283.08 million, a price-to-earnings ratio of -32.17 and a beta of 1.38.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on SMTI shares. HC Wainwright upped their target price on Sanara MedTech from $50.00 to $51.00 and gave the stock a "buy" rating in a research report on Wednesday, March 26th. Cantor Fitzgerald restated an "overweight" rating and set a $46.00 price target on shares of Sanara MedTech in a research note on Wednesday, March 26th.
View Our Latest Report on SMTI
Sanara MedTech Company Profile
(
Get Free Report)
Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sanara MedTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanara MedTech wasn't on the list.
While Sanara MedTech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
